echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Treatment of specific non-small cell lung cancer German Merck MET inhibitors identified as breakthrough therapy

    Treatment of specific non-small cell lung cancer German Merck MET inhibitors identified as breakthrough therapy

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Lung cancer is the most common cancer and one of the world's most serious causes of cancer deathEvery year, 2 million patients are diagnosed with lung cancer, and 1.7 million die from lung cancerIn NSCLC patients, about 3%-5% of patients developmet gene amplification or exosome 14 mutationsWith regard to MET mutation, we do not currently have approved targeted therapies, and the prognosis of these patients is not optimisticTepotinib is a highly selective oral MET inhibitor developed by Merck in Germany that shows antitumor activity in patients with NSCLC overexpression or amplification of METIn addition to being used in clinical trials for NSCLC patients, tepotinib is also treating patients with hepatocellular carcinoma in Phase 2 clinical trialsTepotinib Molecular Structure (Photo: PubChem)the breakthrough therapy is based on ongoing Phase 2 clinical studies called VISIONA total of 73 patients with metastatic NSCLC who had been identified by tissue biopsy (TBx) or liquid biopsy (LBx) with a met exoon 14 jump mutation participated in the trialTrial data suggest that tepotinib may improve treatment options for these patientsFor LBx-confirmed patients, the Independent Review Board (IRC) received a total remission rate (ORR) of 50% and the researchers' results were 55.3%For patients confirmed by TBx, the two figures were 45.1% and 54.9%, respectivelyIn terms of median remission duration (DOR), the IRC gave figures of 12.4 months and 15.7 months, respectively, for patients confirmed by LBx and TBxFor both groups of patients, the researchers gave 17.1 months and 14.3 months, respectively"
    Tepotinib has shown very encouraging overall remission rates and lasting efficacy in patients with metastasis 14-jumping mutations confirmed by TBx or LBx," said DrLuciano Rosettietti, head of global biomedicine research and development at Merck, Germany We look forward to providing this medicine to Patients with NSCLC who may benefit as soon as possible References: , Merck KGaA, Darmstadt, Germany, Announces FDA's Therapy Therapy Therapy For Therapy Tepotinib in Patients Metastatic NSCLC with METex14 Skipping Alterations, RetrievEd Septembered 11, 2019, from the
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.